In plain language
Dulaglutide is a once-weekly injectable medicine that mimics the gut hormone GLP-1 to help control blood sugar. It is FDA-approved for type 2 diabetes, and large human trials support its effects on blood sugar and cardiovascular risk. It is prescription-only.
What it is explored for
Dulaglutide is a convenient once-weekly GLP-1 medicine, FDA-approved for type 2 diabetes and supported by large trials covering both blood sugar and cardiovascular risk. Its simple weekly dosing has made it a well-established option, and its broader metabolic role remains an area of ongoing interest.
- Blood sugar control in type 2 diabetes (FDA-approved)
- Cardiovascular risk reduction demonstrated in trials
- Appetite regulation and reduced food intake
- Convenient once-weekly metabolic support
- Of interest for weight management
- Studied for broader cardiometabolic benefit
These are areas of active interest and reported use, not proven outcomes. This peptide carries a strong (human) rating, see the evidence summary below for how strong the science actually is.
How it works
Dulaglutide links a GLP-1 analog to an immunoglobulin Fc fragment, which extends its half-life and allows once-weekly dosing. It activates the GLP-1 receptor.
- Glucose-dependent insulin release. Stimulates insulin secretion when blood glucose is high, reducing the risk of hypoglycemia.
- Glucagon and gastric emptying. Suppresses post-meal glucagon and slows gastric emptying, which helps blunt blood-sugar spikes.
- Appetite effects. Modestly reduces appetite, which can contribute to weight loss in some people.
These mechanisms are established in humans through large clinical trials and regulatory review.
Evidence summary
Dulaglutide has strong human evidence from the AWARD trial program for glucose control and from the REWIND cardiovascular outcomes trial, which showed a reduction in major cardiovascular events in people with type 2 diabetes. It is an established, approved medicine.
Reported safety & side effects
Common side effects are gastrointestinal (nausea, diarrhea, vomiting). It carries a boxed warning about thyroid C-cell tumors based on rodent data and is used under medical supervision.
Stacking notes
Full stacking guideDo not stack two incretin agonists (for example semaglutide with tirzepatide, or with liraglutide). They act on the same pathway, so side effects like nausea, vomiting, and dehydration add up while there is no evidence of extra benefit. Switch between them under medical care rather than combining.
SemaglutideTirzepatideGeneral educational guidance, not medical advice. Combination evidence is limited; any stack should involve a qualified clinician.
Frequently asked
Is dulaglutide FDA-approved?
Yes. It is approved as Trulicity for type 2 diabetes and is prescription-only.
How often is it taken?
Dulaglutide is designed for once-weekly subcutaneous injection, owing to its long half-life.
Does it help with weight loss?
It can produce modest weight loss as part of diabetes treatment, but it is approved for blood-sugar control rather than as a dedicated weight-loss drug.